Eli Lilly's stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial
Eli Lilly & Co. Inc.'s stock rose 2% following a study comparing Zepbound weight-loss drug to Novo Nordisk's Wegovy, showing Zepbound led to greater weight loss in adults with obesity. Zepbound achieved 20.